Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Last trade$1.42
Day change-$0.24 (-14.46%)
Day range$1.40 – $1.69
Volume35,787
Market cap$10M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$10.37M
Price / earnings
—
Price / book
0.92×
Price / sales
0.31×
EV / sales
-0.61×
EV / EBITDA
0.29×
Profitability
Earnings per share
-$10.61
Return on assets
-140.47%
Return on equity
-586.28%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.01×
Current ratio
1.77×
Quick ratio
1.77×
Cash ratio
1.59×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$68.66M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ALGS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$2.87M
$27.78M
$2.83M
$169K
$741K
$965K
$311K
$629K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$2.87M
$27.78M
$2.83M
$169K
$741K
$965K
$311K
$629K
Selling, general and administrative
$5.87M
$5.62M
$6.41M
$4.95M
$5.17M
$5.56M
$5.05M
$5.16M
Research and development
$18.89M
$24.05M
$23.35M
$17.04M
$23.94M
$13.98M
$14.5M
$16.03M
Total operating expenses
$24.76M
$29.67M
$29.76M
$21.98M
$29.1M
$19.53M
$19.55M
$21.19M
Operating income
-$21.89M
-$1.89M
-$26.93M
-$21.81M
-$28.36M
-$18.57M
-$19.24M
-$20.56M
Interest expense
$169K
$0
$0
$0
$1.09M
$0
$0
$0
Income before taxes
-$21.53M
$1.31M
-$22.72M
-$19.85M
-$31.48M
-$15.68M
$43.13M
-$82.12M
Income taxes
$326K
$2.81M
$317K
$30K
$56K
$185K
$43K
$27K
Net income
-$21.86M
-$1.5M
-$23.04M
-$19.88M
-$31.54M
-$15.86M
$43.09M
-$82.15M
Net income attributable to common shareholders
-$21.86M
-$1.5M
-$23.04M
-$19.88M
-$31.54M
-$15.86M
$43.09M
-$82.15M
EBITDA
-$21.64M
-$1.64M
-$26.58M
-$21.56M
-$28.14M
-$18.31M
-$19.05M
-$20.32M
Basic earnings per share
-$2.09
-$0.14
-$2.21
-$1.91
-$3.04
-$1.53
$5.12
-$13.08
Diluted earnings per share
-$2.09
-$0.14
-$2.21
-$1.97
-$3.04
-$1.53
-$2.11
-$13.09
Recent news
Company coverage with links to the original publishers.
Aligos Therapeutics presented positive Phase 1 follow-up data for pevifoscorvir sodium showing sustained reductions in HBV viral markers and cccDNA reservoir. The company reported that 40% of HBeAg+ participants achieved HBsAg levels below 3,000 IU/mL at week 48, potentially qualifying them for functional cure therapy. Preclinical data demonstrated additive to synergistic effects when combining pevifoscorvir sodium with the ASO ALG-170675.
Aligos Therapeutics has entered into an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium for chronic hepatitis B in Greater China. Aligos will receive a $25M upfront payment and up to $420M in milestone payments plus royalties, while retaining rights in the US, Europe, Japan, and South Korea. The deal extends Aligos' cash runway into Q4 2026.
Aligos Therapeutics reported significant progress in its Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B, completing enrollment of HBeAg- participants with interim analyses expected in 2026. The company also advanced ALG-170675, a dual-mechanism antisense oligonucleotide, into IND-enabling studies in partnership with Xiamen Amoytop Biotech. ALG-055009 showed synergistic weight loss results when combined with incretin receptor agonists. Full year 2025 net loss improved to $24.2 million from $131.2 million in 2024, with cash and investments of $77.8 million expected to fund operations into Q3 2026.
Aligos Therapeutics announced positive clinical data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver. The company presented Phase 1 monotherapy data for pevifoscorvir sodium, a potential first-/best-in-class CAM-E for chronic hepatitis B virus infection, showing high viral suppression. Additionally, Aligos presented pharmacokinetic data for ALG-097558, a pan-coronavirus protease inhibitor, in patients with renal and hepatic impairment.
Aligos Therapeutics announced that its Compensation Committee granted non-qualified stock options to purchase 81,100 shares to newly hired employees on January 29, 2026, as an inducement for employment. The options have an exercise price equal to the closing stock price on the grant date and will vest over four years with 25% vesting on the first anniversary.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.